JPWO2020168110A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020168110A5
JPWO2020168110A5 JP2021547322A JP2021547322A JPWO2020168110A5 JP WO2020168110 A5 JPWO2020168110 A5 JP WO2020168110A5 JP 2021547322 A JP2021547322 A JP 2021547322A JP 2021547322 A JP2021547322 A JP 2021547322A JP WO2020168110 A5 JPWO2020168110 A5 JP WO2020168110A5
Authority
JP
Japan
Prior art keywords
therapy
pharmaceutical composition
treatment
cancer
sephb4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520596A5 (https=
JP2022520596A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018160 external-priority patent/WO2020168110A1/en
Publication of JP2022520596A publication Critical patent/JP2022520596A/ja
Publication of JPWO2020168110A5 publication Critical patent/JPWO2020168110A5/ja
Publication of JP2022520596A5 publication Critical patent/JP2022520596A5/ja
Pending legal-status Critical Current

Links

JP2021547322A 2019-02-13 2020-02-13 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対 Pending JP2022520596A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805291P 2019-02-13 2019-02-13
US62/805,291 2019-02-13
PCT/US2020/018160 WO2020168110A1 (en) 2019-02-13 2020-02-13 Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer

Publications (3)

Publication Number Publication Date
JP2022520596A JP2022520596A (ja) 2022-03-31
JPWO2020168110A5 true JPWO2020168110A5 (https=) 2023-02-21
JP2022520596A5 JP2022520596A5 (https=) 2023-02-21

Family

ID=72045655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547322A Pending JP2022520596A (ja) 2019-02-13 2020-02-13 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対

Country Status (8)

Country Link
US (1) US20220153791A1 (https=)
EP (1) EP3923969A4 (https=)
JP (1) JP2022520596A (https=)
KR (1) KR20220010469A (https=)
CN (1) CN114007633A (https=)
AU (1) AU2020221276A1 (https=)
CA (1) CA3139416A1 (https=)
WO (1) WO2020168110A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2020190977A1 (en) * 2019-03-17 2020-09-24 Vasgene Therapeutics Inc Treatment of cancers using sephb4-hsa fusion proteins
CA3211742A1 (en) * 2021-03-18 2022-09-22 Valery Krasnoperov Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
CN118290563B (zh) * 2024-06-03 2024-08-02 磐如生物科技(天津)有限公司 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2012068477A1 (en) * 2010-11-19 2012-05-24 Vasgene Therapeutics, Inc. Methods and compositions for inhibiting angiogenesis and tumor growth
EP2922861A4 (en) * 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
WO2020190977A1 (en) * 2019-03-17 2020-09-24 Vasgene Therapeutics Inc Treatment of cancers using sephb4-hsa fusion proteins

Similar Documents

Publication Publication Date Title
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP4202417B2 (ja) Ｉｌ−１３受容体特異的キメラタンパク質およびその用途
ES2373966T3 (es) Composiciones y procedimientos para el tratamiento de la angiogénesis en lesiones patológicas.
US10195253B2 (en) Immunocytokine combination therapy
CN1318450C (zh) 修饰和嵌合的超抗原及其用途
ES2382058T3 (es) Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
US6518061B1 (en) IL-13 receptor specific chimeric proteins and uses thereof
JP2016537340A5 (https=)
JP6682438B2 (ja) 癌治療のための改善された細胞組成物および方法
AU2018266562A1 (en) Human alpha fetoprotein-specific T cell receptors and uses thereof
RS66435B1 (sr) Dozni režim za gp100-specifični tcr - anti-cd3 scfv fuzioni protein
PL185364B1 (pl) Kompozycje farmaceutyczne do leczenia albo zmniejszenia zaawansowania, ciężkości albo skutków powstawania nowotworu
JP2024517871A (ja) プロテアーゼ活性化治療剤を含む組成物および方法
AU2016274897A1 (en) Focused interferon immunotherapy for treatment of cancer
JP2016505807A (ja) Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
JP2023508047A (ja) Ｉｌ－２受容体作動薬及び免疫チェックポイント阻害薬を使用する併用療法
JPWO2020168110A5 (https=)
CA3147832A1 (en) Antibodies that bind to lrp6 proteins and methods of use
CN115304680B (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
US20030129132A1 (en) IL-13 receptor specific chimeric proteins & uses thereof
JPWO2020190977A5 (https=)
AU2024298986C1 (en) Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof
US20250312470A1 (en) A pharmaceutical composition of anti-her2 antibody-immune agonist conjugate and applications thereof
KR20250092133A (ko) 면역억제성 종양미세환경을 조절하는 항체-펩타이드 융합체 및 이의 항암용도
HK40088389A (zh) 针对folr1的双特异性抗体及其用途